Gilead Sciences Moves to Acquire Ouro Medicines, Strengthening Its Autoimmune and Inflammation Pipeline with Innovative T-Cell Engager Technology
Gilead Sciences has announced a major strategic step to expand its presence in the autoimmune disease space through a definitive agreement to acquire Ouro Medicines, a privately held biotech firm focused on developing next-generation T-cell engager therapies. The deal reflects Gilead’s ongoing commitment to advancing innovative treatments for serious inflammatory and autoimmune disorders, areas of significant unmet medical need.
At the heart of this acquisition is OM336 (also known as gamgertamig), a clinical-stage bispecific antibody designed to target BCMA (B-cell maturation antigen) and CD3. This dual-targeting mechanism allows the therapy to redirect T cells toward pathogenic B cells and plasma cells, which play a central role in many autoimmune diseases. By eliminating these harmful cells, OM336 aims to reset the immune system and potentially provide long-lasting disease control after a limited course of treatment.
Expanding Gilead’s Inflammation Portfolio
The addition of OM336 represents a significant enhancement to Gilead’s growing inflammation and immunology portfolio. The therapy is currently being evaluated in Phase 1/2 clinical trials and has already shown encouraging results. Early data suggest that a single treatment cycle may deliver deep and rapid B-cell depletion, along with a favorable safety profile. These findings are particularly notable in severe, antibody-mediated orphan diseases such as autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP).
Both AIHA and ITP are rare but serious conditions in which the immune system mistakenly attacks blood components, leading to anemia or low platelet counts, respectively. Patients with these disorders often require long-term immunosuppressive therapy, which can come with significant side effects and inconsistent outcomes. The potential for OM336 to induce durable remission without continuous treatment could represent a meaningful advancement in care.
The U.S. Food and Drug Administration (FDA) has already granted OM336 both Fast Track and Orphan Drug Designations for AIHA and ITP, underscoring its potential to address unmet clinical needs. Gilead expects the therapy to advance into registrational studies by 2027, marking a critical milestone in its development pathway.
A Novel Approach to Autoimmune Disease Treatment
T-cell engagers like OM336 are gaining attention as a promising new therapeutic modality in autoimmune diseases. Unlike traditional treatments that broadly suppress the immune system, these therapies offer a more targeted approach. By leveraging the body’s own immune cells, they can selectively eliminate disease-causing cells while preserving overall immune function.
BCMA, the target of OM336, is already well validated in oncology, particularly in multiple myeloma. However, its application in autoimmune diseases represents an emerging and potentially transformative area of research. Early clinical data suggest that targeting BCMA-expressing plasma cells may not only reduce inflammation but also enable what researchers describe as an “immune reset.” This reset could allow patients to achieve long-term remission without ongoing immunosuppression—a major goal in the field.
Gilead believes that integrating T-cell engager therapies with its existing portfolio, which includes CAR-T cell therapies, will provide a comprehensive approach to treating immune-mediated diseases. Together, these modalities could offer both immediate and durable solutions for patients with complex conditions.
Leadership Perspective on the Acquisition
According to Gilead’s Chief Medical Officer, Dietmar Berger, the acquisition aligns closely with the company’s broader strategic vision. He emphasized that BCMA-targeted therapies have already demonstrated strong potential in early studies and could significantly improve outcomes for patients with autoimmune diseases.
The leadership at Ouro Medicines also expressed optimism about the transaction. Jaideep Dudani, the company’s co-founder and CEO, highlighted the progress made in advancing gamgertamig through early clinical development. He noted that partnering with Gilead would provide the resources and expertise needed to accelerate development, particularly in late-stage trials and commercialization.
Dudani also pointed to the importance of collaboration in bringing innovative therapies to market. Ouro’s earlier partnership with Keymed Biosciences laid the groundwork for the current progress, and the new agreement is expected to build on that foundation.
Financial Terms of the Deal
Under the terms of the agreement, Gilead will acquire all outstanding equity of Ouro Medicines for an upfront payment of $1.675 billion in cash. This amount is subject to customary adjustments and will be paid at the time of closing. In addition, Ouro shareholders may receive up to $500 million in milestone-based payments, contingent on the achievement of specific development and commercial goals.
The transaction is expected to close once all regulatory requirements and customary conditions have been satisfied. Financial advisory services for the deal were provided by leading firms, including Centerview Partners and TD Cowen for Gilead, and Goldman Sachs for Ouro Medicines.
Potential Collaboration with Galapagos
In parallel with the acquisition, Gilead is engaged in advanced discussions with Galapagos regarding a potential research and development collaboration centered on the newly acquired Ouro assets. If finalized, this partnership would further strengthen the development and commercialization strategy for OM336 and related therapies.
The proposed collaboration includes a cost-sharing arrangement in which Galapagos would contribute 50% of the upfront acquisition cost and any subsequent milestone payments. Additionally, Galapagos would take on a significant portion of Ouro’s operational infrastructure, including its workforce.
Under the anticipated agreement, Galapagos would be responsible for funding development activities up to the initiation of registrational studies. Beyond that point, both companies would share development costs equally. This structure is designed to balance financial risk while accelerating the timeline for bringing new therapies to market.
Gilead would retain exclusive global commercialization rights for OM336, except in Greater China, where Keymed Biosciences holds existing rights. In return, Galapagos would receive tiered royalties ranging from 20% to 23% of net sales.
Broader Strategic Implications
The acquisition of Ouro Medicines and the potential collaboration with Galapagos reflect a broader trend in the biopharmaceutical industry toward targeted, precision-based therapies. As understanding of immune system mechanisms deepens, companies are increasingly focusing on approaches that can deliver durable outcomes with fewer side effects.
For Gilead, this deal represents more than just the addition of a promising drug candidate. It signals a continued evolution of the company’s strategy, with a growing emphasis on immunology and inflammation alongside its established strengths in virology and oncology.
The integration of T-cell engager technology into Gilead’s pipeline could open new avenues for treating a wide range of autoimmune conditions. If successful, therapies like OM336 may redefine the standard of care by offering patients the possibility of long-term remission without the need for continuous treatment.
Conclusion
Gilead Sciences’ acquisition of Ouro Medicines marks a significant milestone in the development of innovative therapies for autoimmune diseases. By adding a first-in-class BCMAxCD3 T-cell engager to its portfolio, the company is positioning itself at the forefront of a rapidly evolving field.
With strong early clinical data, regulatory support, and the potential for strategic collaboration with Galapagos, OM336 represents a promising new approach to treating severe immune-mediated conditions. As the therapy advances toward late-stage development, it could play a key role in transforming how autoimmune diseases are managed in the future.
About OM336
OM336 is an investigational BCMAxCD3 bispecific T cell engager for the treatment of autoantibodies driven immune-mediated disease. OM336 has been granted Orphan Drug Designation and Fast Track Designation by the U.S. Food and Drug Administration for certain autoimmune diseases. OM336 is under an open IND in the U.S. and is expected to enter registrational studies in 2027. OM336 is in-licensed by Ouro Medicines from Keymed Biosciences, which owns the rights to develop the program in Greater China.
About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, Calif.
About Ouro Medicines
Ouro Medicines is a clinical stage biotechnology company dedicated to developing immune reset therapeutics for people living with chronic immune-mediated diseases. Ouro’s approach is focused on leveraging T cell engagers in B cell-mediated diseases to achieve immune resets that create durable remissions without ongoing immunosuppression. Based in San Francisco and launched in 2025, Ouro was founded by Monograph Capital in partnership with GSK. Ouro is also backed by leading investors TPG, NEA and Norwest
